Neuroscientists at Fudan University have made a groundbreaking discovery in understanding the biological mechanism that connects chronic pain with clinical depression. Their research, published in the prestigious journal Science, reveals a specific neural gateway within the hippocampus that determines whether persistent physical pain transforms into debilitating mental health conditions.
The comprehensive study, conducted at the university’s Institute of Science and Technology for Brain-inspired Intelligence, analyzed neuroimaging data from 30,000 human subjects alongside animal models. The research team identified that the hippocampus, traditionally known for memory and navigation functions, serves as a critical mood regulation center. During initial pain exposure, this brain region demonstrates enhanced functionality and temporary enlargement as a defensive mechanism.
Dr. Xiao Xiao, co-corresponding author and executive director of the institute’s behavioral and cognitive neuroscience center, explained the transformative process: “As pain transitions from acute to chronic, we observe progressive hippocampal atrophy accompanied by diminished regulatory capacity. This deterioration coincides with the emergence of depressive symptoms.”
The investigation pinpointed the dentate gyrus (DG) sub-region as the specific neurological gatekeeper. This area possesses unique neuroplasticity capabilities, generating new neurons to help the brain adapt to stress. However, chronic pain triggers microglia—the brain’s immune cells—to become hyperactive, disrupting electrical signal balance and causing the emotion gate to malfunction.
The findings suggest revolutionary clinical applications. Rather than solely addressing pain symptoms, medical professionals could employ brain imaging to monitor hippocampal health and implement preventive interventions before structural deterioration occurs. The research team successfully tested an established clinical drug that regulates microglia activity, demonstrating its potential for rapid translation to patient treatment.
Initiated in 2018, the research program now incorporates artificial intelligence to screen for novel small-molecule drugs targeting specific brain cells. The scientists believe genetic predispositions and environmental factors contribute to individual variations in emotional resilience among pain patients.